Related Experiment Video
Updated: Jan 31, 2026

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
To Give or Not to Give: The Challenge of Pharmaceutical Coupons
Mihail Zilbermint1, Louise Schiavone2
1Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine in Baltimore, Maryland USA; Endocrinology, Diabetes, and Metabolism, Suburban Hospital, Bethesda, Maryland USA; Endocrinology, Diabetes, and Metabolism, Johns Hopkins Community Physicians, Suburban Hospital, Bethesda, Maryland USA; Johns Hopkins Carey Business School, Baltimore, Maryland USA. mzilber3@ jhmi.edu.
Abstract:
Diabetes is epidemic and many people cannot afford insulin, a lifesaving medication, as its price has increased by almost 160 percent in the past five years.1 To help subsidize the cost of insulin, one of the staff members at my hospital would like to give patients copayment coupons provided to her by pharmaceutical companies. I advised my colleague to stop distributing these branded coupons, as they promote particular pharmaceutical companies. This practice is not consistent with the policy on interaction with industry established by the Johns Hopkins Health System. Yet at the same time, I want my patients to be able to afford their insulin so they can treat their diabetes. I truly believe in utilitarianism. Would temporarily subsidizing patients' insulin make me and my staff better healthcare providers? Would this minimize my patients' financial burden? Would giving away medications coupons help pharmaceutical companies influence me as a prescriber? This challenge created a personal internal debate and profound moral distress.
More Related Videos
Related Concept Videos
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Attribution Theory

